• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Benefit of Single Antiplatelet Therapy Over Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation
Current practice guidelines recommend dual antiplatelet therapy with aspirin and clopidogrel for 3-6 months followed by lifelong aspirin after transcatheter aortic valve implantation (TAVI). However, recently published POPular TAVI trial1 and other trials2 –4 that have compared dual antiplatelet therapy (DAPT) with single antiplatelet therapy (SAPT) have shown decreased bleeding events and non-inferiority with respect to ischemic stroke, all-cause mortality, and myocardial infarction (MI) amongst patients receiving SAPT.
Source: The American Journal of Cardiology - December 8, 2020 Category: Cardiology Authors: Agam Bansal, Ashish Kumar, Vardhmaan Jain, Grant W Reed, Amar Krishnaswamy, Ankur Kalra, Rishi Puri, Samir R. Kapadia Source Type: research

Meta-analysis Of Randomized Controlled Trials and Adjusted Observational Results Of Use Of Clopidogrel, Aspirin and Oral Anti-coagulants In Patients Undergoing Percutaneous Coronary Intervention
The optimal antiaggregant therapy after coronary stenting in patients receiving oral anticoagulation (OAC) is currently debated. Medline and Cochrane Library were searched for studies reporting outcomes of patients undergoing PCI and who were on triple therapy (TT)or dual antiplatelet therapy (DAPT) with aspirin and clopidogrel or dual therapy(DT) with OAC and clopidogrel. Major bleeding was the primary end point, while all-cause death, myocardial infarction (MI), stent thrombosis and stroke were secondary ones.
Source: The American Journal of Cardiology - February 11, 2015 Category: Cardiology Authors: Fabrizio D’Ascenzo, Salma Taha, Claudio Moretti, Pierluigi Omedè, Walter Grossomarra, Jonas Persson, Morten Lamberts, Willem Dewilde, Andrea Rubboli, Sergio Fernández, Enrico Cerrato, Ilaria Meynet, Flavia Ballocca, Umberto Barbero, Giorgio Quadri, Fr Source Type: research

Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.
Source: The American Journal of Cardiology - June 20, 2014 Category: Cardiology Authors: Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, Philip E. Aylward, Paul W. Armstrong, Frans Van de Werf, Sergio Leonardi, Harvey D. White, Petr Widimsky, Robert A. Harrington, Angel Cequier, Edmond Chen, Yuliya Lokhnygina, Lars Wallentin, John Strony, Ke Tags: Coronary Artery Disease Source Type: research

Impact of Dual Antiplatelet Therapy on Outcomes Among Aspirin-Resistant Patients Following Coronary Artery Bypass Grafting
This study was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end point was a composite outcome of all-cause death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months postoperatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of patients rando...
Source: The American Journal of Cardiology - March 3, 2014 Category: Cardiology Authors: Hrvoje Gasparovic, Mate Petricevic, Tomislav Kopjar, Zeljko Djuric, Lucija Svetina, Bojan Biocina Tags: Coronary Artery Disease Source Type: research

Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry SCAAR)
In conclusion, in this real world population of patients who underwent urgent or elective PCI, prasugrel was used mainly in patients with ACS, while it was avoided in patients with characteristics indicating increased bleeding risk. Mortality and bleeding rates were lower with prasugrel than clopidogrel, probably because of patient selection.
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Peter Damman, Christoph Varenhorst, Sasha Koul, Peter Eriksson, David Erlinge, Bo Lagerqvist, Stefan K. James Tags: Coronary Artery Disease Source Type: research

Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP VerifyNow and Inhibition of Platelet Reactivity Study)
In conclusion, 1/3 of patients with acute coronary syndromes who underwent percutaneous coronary intervention and stenting showed high on-treatment RPR on bedside monitoring. They had a worse prognosis, but the level of platelet inhibition was not independently associated with the incidence of ischemic or bleeding events.
Source: The American Journal of Cardiology - June 7, 2013 Category: Cardiology Authors: Francesco Saia, Massimiliano Marino, Gianluca Campo, Marco Valgimigli, Paolo Guastaroba, Nevio Taglieri, Stefano Tondi, Antonio Manari, Vincenzo Guiducci, Pietro Sangiorgio, Elisabetta Varani, Paolo Magnavacchi, Rossana De Palma, Antonio Marzocchi Tags: Coronary Artery Disease Source Type: research

Thrombocytopenia in Patients With Atrial Fibrillation on Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
In conclusion, mild to moderate baseline thrombocytopenia does not seem to have a clinically significant effect on bleeding or thrombotic or thromboembolic complications after PCI in these frail patients receiving multiple antithrombotic drugs.
Source: The American Journal of Cardiology - May 13, 2013 Category: Cardiology Authors: Tuomas Kiviniemi, Pasi Karjalainen, Andrea Rubboli, Axel Schlitt, Petri Tuomainen, Matti Niemelä, Mika Laine, Fausto Biancari, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Coronary Artery Disease Source Type: research